transmission of HIV and AIDS, even if legal drug is available. A clinical trial is therefore needed to evaluate the efficacy and safety of this new approach. A placebo-controlled, randomized trial comparing the open-label drug and placebo in a population of HIV-infected individuals would be necessary. The trial should be designed to evaluate the effectiveness of the open-label drug compared to placebo in reducing the risk of transmission of HIV and AIDS.